NHSA Launches Intelligent Supervision Reform Pilot in Designated Medical Institutions
The National Healthcare Security Administration (NHSA) has released a notification to implement an intelligent supervision...
Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing...
OUR United Corporation Files for IPO in Hong Kong Stock Exchange
China-based OUR United Corporation, a leading provider of radiosurgical solutions, has filed for an initial...
Henlius Biotech’s HLX22 Receives Clinical Trial Approval in Germany for HER2-Positive Cancers
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received clinical trial approval...
GenScript to Acquire Additional Stake in Probio Cayman for USD 225.1 Million
GenScript Biotech Corporation (HKG: 1548) is set to acquire an additional 300 million Class A...
CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8%...
Innovent Biologics Posts 51.8% YOY Revenue Growth in 2024 Financial Report
China-based Innovent Biologics, Inc. (HKG: 1801) released its 2024 financial report, highlighting a robust growth...
Hengrui Pharmaceuticals Gains NMPA Clinical Clearance for Camrelizumab in Acral Melanoma
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...
Shouyao Holdings Unveils RMB787 Million Investment in Beijing BioPark R&D and GMP Facility
Shanghai-listed biopharmaceutical company Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) has announced plans to invest...
Biokin’s BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply
German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China)...
CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors
Zhejiang-based Zhejiang Shimai Pharmaceutical Co.，Ltd (CentryMed)’s CMDE005, an anti-EGFR×CD3 enzyme-controlled bispecific antibody (BsAb) developed using...
Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy
US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval...
Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...
Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the first prescription of AcornMed utLIFE-UC,...
Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has secured marketing approval...
Roche’s Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported Q1 2025 financials with global group...
BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...
Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China
Global pharmaceutical company Merck (NYSE: MRK) released its Q1 2025 financial results, showing total sales...